FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4232188745> ?p ?o ?g. }

• W4232188745 endingPage "1829" @default.
• W4232188745 startingPage "1829" @default.
• W4232188745 abstract "An orally bioavailable MC4 antagonist with in vivo efficacy in animal models of cachexia. Cachexia is defined as a loss of weight, muscle atrophy and fatigue coupled with an extreme loss of appetite in an individual not actively attempting to lose weight [1]. Often seen in end-stage cancer, cachexia is often referred to as ‘cancer cachexia’ in this context and physically weakens cancer patients to a state of immobility [1]. Moreover, cancer cachexia significnatly impacts patients quality of life, diminishes their response to standard chemotherapy and leads to increased rates of morbitiy and mortality [1-3]. Sadly, the currently available treatments for cancer cachexia are not very effective [1-3]. Recently, Chen and co-workers from Neuocrine Biosciences reported (J. Med. Chem. 2007, 50, 5249-5252) on a potential new treatment for cancer cachexia by antagonism of the melanocortin-4 receptor (MC4R) with an orally bioavailble small molecule [3]. The MC4 receptor is a member of the class A G protein-coupled receptor (GPCR) family and there are five subtypes of melanocortin receptors (MC1-5). MC4 is expressed in various regions of the brain, and plays a critical role in regulating feeding behavior and energy homeostatsis in both animals and humans [3]. MC4 agonists have been shown to suppress food intake and reduce body weight in animals, suggesting agonim of MC4 may be a theraputic approach for the treatment of obesity [3]. In contrast, MC4 antagonists have been demonstarted to promote food intake and increase weight gain [3]. After extensive lead optimization efforts, Chen and co-workers identified 1, of 1-{2-[(1S)-(3-dimethylaminopropionyl)amino-2- methylpropyl]-4-methylphenyl}-4-[(2R)-methyl-3-(4-chlorophenyl)- propionyl]piperazine, a potent (MC4 Ki = 2.8 nM, IC50 = 35 nM) and selective ( > 125-fold selective versus MC1, MC3, MC5) MC4 antagonist [3]. MC4 antagonist 1 possessed excellent aqueous solubility ( > 33 mg/mL at pH 7 and > 71 mg/mL at pH 3), a good metabolic profile (no significant CYP inhibition, not a P-gp substrate (B/A-A/B = 1.9)) and good oral bioavailability (32%) in mice (as well as across species: rat, 43%, dog, 19%, rhesus, 19%). Despite a low to moderate brain/plasma ratio of 0.17 (based on AUCs), MC4 antagonist 1 significantly increased food intake on days 10-12 in Lewis lung carcinoma (LLC) tumor-bearing mice when dosed at either 5 or 20 mg/kg p.o. compared to tumor-bearing vehicle treated animals. Thus, selective antagonism of MC4 with small molecules holds promise as a potential new treatment for patients suffering from cancer cachexia, a truly unmet medical need. REFERENCES [1] www.wikipedia.com search string: cachexia [2] Bossola, M.; Pacceli, F.; Tortorelli, A.; Doglietto, G.B. ‘Cancer cachexia: Its time for more clinical trials’ Ann. Surg. Oncol. 2007, 14, 276-285. [3] Chen, C.; Jiang, W.; Tucci, F.; Tran, J.A.; Fleck, B.A.; Hoare, S.R.; Joppa, M.; Markison, S.; Wen, J.; Sai, Y.; Johns, M.; Madam, A.; Chen, T.; Chen, C.W.; Marinkovic, D.; Arellano, M.; Saunders, J. Foster, A.C. ‘Discovery of 1-{2-[(1S)-(3-dimethylaminopropionyl) amino-2-methylpropyl]-4-methylphenyl}-4-(2R)-methyl-3-(4-chlorophenyl)- propionyl]piperazine as an orally active antagonist of the melanocortin receptor for the potential treatment of cachexia’ J. Med. Chem. 2007, 50, 5249-5252, and references therein." @default.
• W4232188745 created "2022-05-12" @default.
• W4232188745 creator A5060483072 @default.
• W4232188745 date "2007-09-01" @default.
• W4232188745 modified "2023-09-26" @default.
• W4232188745 title "Molecule of the Month" @default.
• W4232188745 doi "https://doi.org/10.2174/156802607782507439" @default.
• W4232188745 hasPublicationYear "2007" @default.
• W4232188745 type Work @default.
• W4232188745 citedByCount "7" @default.
• W4232188745 countsByYear W42321887452014 @default.
• W4232188745 countsByYear W42321887452017 @default.
• W4232188745 crossrefType "journal-article" @default.
• W4232188745 hasAuthorship W4232188745A5060483072 @default.
• W4232188745 hasConcept C121608353 @default.
• W4232188745 hasConcept C126322002 @default.
• W4232188745 hasConcept C134018914 @default.
• W4232188745 hasConcept C151730666 @default.
• W4232188745 hasConcept C170493617 @default.
• W4232188745 hasConcept C2777704314 @default.
• W4232188745 hasConcept C2779343474 @default.
• W4232188745 hasConcept C2779764123 @default.
• W4232188745 hasConcept C2779993316 @default.
• W4232188745 hasConcept C2911126609 @default.
• W4232188745 hasConcept C43295716 @default.
• W4232188745 hasConcept C511355011 @default.
• W4232188745 hasConcept C544821477 @default.
• W4232188745 hasConcept C60644358 @default.
• W4232188745 hasConcept C71924100 @default.
• W4232188745 hasConcept C75908981 @default.
• W4232188745 hasConcept C86803240 @default.
• W4232188745 hasConceptScore W4232188745C121608353 @default.
• W4232188745 hasConceptScore W4232188745C126322002 @default.
• W4232188745 hasConceptScore W4232188745C134018914 @default.
• W4232188745 hasConceptScore W4232188745C151730666 @default.
• W4232188745 hasConceptScore W4232188745C170493617 @default.
• W4232188745 hasConceptScore W4232188745C2777704314 @default.
• W4232188745 hasConceptScore W4232188745C2779343474 @default.
• W4232188745 hasConceptScore W4232188745C2779764123 @default.
• W4232188745 hasConceptScore W4232188745C2779993316 @default.
• W4232188745 hasConceptScore W4232188745C2911126609 @default.
• W4232188745 hasConceptScore W4232188745C43295716 @default.
• W4232188745 hasConceptScore W4232188745C511355011 @default.
• W4232188745 hasConceptScore W4232188745C544821477 @default.
• W4232188745 hasConceptScore W4232188745C60644358 @default.
• W4232188745 hasConceptScore W4232188745C71924100 @default.
• W4232188745 hasConceptScore W4232188745C75908981 @default.
• W4232188745 hasConceptScore W4232188745C86803240 @default.
• W4232188745 hasIssue "18" @default.
• W4232188745 hasLocation W42321887451 @default.
• W4232188745 hasOpenAccess W4232188745 @default.
• W4232188745 hasPrimaryLocation W42321887451 @default.
• W4232188745 hasRelatedWork W1973484955 @default.
• W4232188745 hasRelatedWork W1973961610 @default.
• W4232188745 hasRelatedWork W1979467063 @default.
• W4232188745 hasRelatedWork W1989131318 @default.
• W4232188745 hasRelatedWork W2006467783 @default.
• W4232188745 hasRelatedWork W2007059286 @default.
• W4232188745 hasRelatedWork W2057940121 @default.
• W4232188745 hasRelatedWork W2140550416 @default.
• W4232188745 hasRelatedWork W2169411907 @default.
• W4232188745 hasRelatedWork W4232188745 @default.
• W4232188745 hasVolume "7" @default.
• W4232188745 isParatext "false" @default.
• W4232188745 isRetracted "false" @default.
• W4232188745 workType "article" @default.